Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nivolumab with radiotherapy, with or without cisplatin, in locally advanced squamous cell carcinoma of the head and neck
2017-002676-87Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab and cisplatin in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Event-free survival. Started Jan 2018; status: completed.
02
Drugs
nivolumabcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-002676-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002676-87.